The price of Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares last traded on Wall Street fell -4.90% to $1.36.
RANI stock price is now -29.20% away from the 50-day moving average and -59.04% away from the 200-day moving average. The market capitalization of the company currently stands at $78.10M.
With the price target of $17, Oppenheimer recently initiated with Outperform rating for Rani Therapeutics Holdings Inc (NASDAQ: RANI). On June 14, 2024, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Rodman & Renshaw’ rates the stock as ‘Buy’
In other news, McKinley Kate, Chief Business Officer bought 17,960 shares of the company’s stock on Dec 13 ’24. The stock was bought for $29,993 at an average price of $1.67. Upon completion of the transaction, the Chief Business Officer now directly owns 17,960 shares in the company, valued at $24425.6. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09 ’24, Chief Executive Officer Imran Talat bought 10,296 shares of the business’s stock. A total of $19,974 was incurred on buying the stock at an average price of $1.94. This leaves the insider owning 494,751 shares of the company worth $0.67 million. A total of 31.51% of the company’s stock is owned by insiders.
During the past 12 months, Rani Therapeutics Holdings Inc has had a low of $1.30 and a high of $8.75. As of last week, the company has a debt-to-equity ratio of 10.81, a current ratio of 1.60, and a quick ratio of 1.60. The fifty day moving average price for RANI is $1.9404 and a two-hundred day moving average price translates $3.33008 for the stock.
The latest earnings results from Rani Therapeutics Holdings Inc (NASDAQ: RANI) was released for 2024-06-30. The company reported revenue of $11.8 million for the quarter, compared to $17.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -33.92 percent.
